The George Washington University Cancer Institute has finalized 45 core competency statements for oncology patient navigators, who have become critical members of the health care team.
The George Washington University (GW) Cancer Institute has finalized 45 core competency statements for oncology patient navigators, who have become critical members of the healthcare team. These competency statements were published in the Journal of Oncology Navigation and Survivorship and were created through literature review, focus group data analysis, expert review, and a national survey of oncology patient navigation stakeholders.
"Patient navigation is a rapidly growing health profession given new accreditation standards from the American College of Surgeons' Commission on Cancer. However, patient navigation suffers from a lack of standardization or regulation of any kind," said Mandi Pratt-Chapman, MA, lead author and director of the GW Cancer Institute, which is housed within the GW School of Medicine and Health Sciences. "This means that patient navigator practices vary widely, sometimes performing administrative duties that underutilize unique skills and sometimes performing services that should be left to clinically-licensed healthcare professionals. The GW Cancer Institute Core Competencies for Oncology Patient Navigators are the first-ever consensus-based standards for the field to advance the profession and ensure we optimize all members of the healthcare team to support great patient care."
Link to the complete article on MedicalXpress: http://bit.ly/1NRgOVt
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
2 Commerce Drive
Cranbury, NJ 08512